Characteristics, Treatment Options for Patients With Advanced Gynecologic Cancers
A presentation at the 2023 ONA Summit reviewed diagnosis and treatment recommendations for uterine, ovarian, and endometrial cancers.
Headlines
Update on Therapeutic Options for Myelofibrosis
A review of myelofibrosis, including an update on treatment options, was presented at the 2023 ONA Summit.
New Treatments, New Challenges in the Treatment of Bladder and Renal Cancers
A discussion of new treatment options that have improved prognosis for patients with bladder cancer and renal cell carcinoma is the focus of a presentation at the 2023 ONA Summit.
Advanced Gastric and Colorectal Cancer Diagnosis and Treatment
Management strategies aimed at improving outcomes in patients with CRC and gastric cancer were presented at the 2023 ONA Summit.
Treatment Selection and Symptom Management After MDS/MDN Diagnosis
A review of MDS/MDN, including new WHO guidelines and collaborative strategies for managing the care of patients with lower-risk MDS.
Pivotal Studies Lead to New Treatment Landscape for Metastatic HER2-Positive Breast Cancer
A review of patient assessment, treatment options, and management strategies for adverse effects in patients with metastatic HER2-positive breast cancer were presented at the 2023 ONA Summit.
Updates in Targeted Therapies, Management Strategies for Non-Small Cell Lung Cancer
In an oral presentation at the 2023 ONA Summit, a thoracic oncology nurse practitioner reviewed the advances in the treatment of NSCLC and management of related adverse effects.
Achieving, Managing Patient Care During Maintenance Therapy for AML
The unique needs of patients with AML undergoing maintenance therapy, including care disparities and challenges, are discussed at the 2023 ONA Summit.
ONA Summit Highlights Collaboration, How Oncology Nurses Thrive Under Pressure
Here is a preview of this year’s ONA Summit with a link to the registration page.
Recurrences and Deaths Prevented by Atezolizumab Translate to Lower Cost of Care
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...